|
BR112017023762A2
|
|
injectable depot formulations
|
|
WO2016176579A1
|
|
Injectable sustained release intraocular device
|
|
EP2968882A1
|
|
Drug delivery device comprising silicon-based carrier particles
|
|
WO2014165108A1
|
|
Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
|
|
CN104105513A
|
|
Injector apparatus with fixed plunger and method of use
|
|
WO2012109673A1
|
|
Methods of treating macular edema using antiedema therapeutics
|
|
WO2012088304A2
|
|
Two-piece injectable drug delivery device with heat-cured seal
|
|
CA2816576A1
|
|
Bioerodible silicon-based devices for delivery of therapeutic agents
|
|
EP2515864A1
|
|
Sustained release delivery devices
|
|
US2010247607A1
|
|
Implantable formulations of bisphosphonic acids
|
|
US2008220062A1
|
|
Sustained release of agents for localized pain management
|
|
WO2008033426A1
|
|
Injector apparatus and method of use
|
|
EP1916976A2
|
|
Control of induced elevated intraocular pressure
|
|
EP1909848A2
|
|
HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
|
|
EP1868653A2
|
|
Hmgcoa reductase inhibitor codrugs and uses thereof
|
|
CN1901850A
|
|
Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
|
|
EP2044959A1
|
|
In-situ gelling drug delivery system
|
|
MY135804A
|
|
Processes of forming a drug delivery device
|
|
AU2003205278B2
|
|
Polymeric gel system for the controlled delivery of codrugs
|
|
CN1589166A
|
|
Stent coated with a sustained-release drug delivery system and method for use thereof
|
